📰 Objective Response Rate News
Page 7 - Objective Response Rate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Objective Response Rate. Real-time updates on events, politics, business and more.
November 10, 2022
PALM BEACH, Fla., Nov. 10, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market competition
November 10, 2022
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...
October 28, 2022
Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities,...
October 28, 2022
Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities,...
October 28, 2022
Nuvalent, Inc. announced the initial data from the Phase 1 dose-escalation portion of its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell... | October 28, 2022
October 6, 2022
GSK stock has endured a torrid year-to-date - down 21% in a sector that is performing much better than the S&P. Click here to read my analysis of GSK stock.
October 4, 2022
/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing...
October 4, 2022
/PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing...
September 13, 2022
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer
September 9, 2022
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development planned